Potential therapeutic application of antisense oligonucleotides in the treatment of ocular diseases

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 2, 2001, Pages 277-291

  Henry, S P ^a   Danis, R P ^a  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antisense; Diabetic retinopathy; Glaucoma; Macular degeneration; Ocular infection; Oligonucleotides; Uveitis

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CORTICOSTEROID; FOMIVIRSEN; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 2 RECEPTOR ANTIBODY; ISIS 13312; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONOCLONAL ANTIBODY; PADGEM PROTEIN; PROTEIN BAX; RECOMBINANT ANTIBODY; TRANSFORMING GROWTH FACTOR BETA2; VASCULOTROPIN INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DESIGN; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESEARCH; EYE DISEASE; EYE INFECTION; EYE INFLAMMATION; GENE TECHNOLOGY; GLAUCOMA; HUMAN; MOLECULAR BIOLOGY; MONKEY; MOUSE; NONHUMAN; PATHOLOGY; PHYSIOLOGY; RABBIT; RAT; RETINITIS; REVIEW; SCAR FORMATION; STRUCTURE ACTIVITY RELATION; SWINE; UVEITIS;

ANIMALS; EYE DISEASES; GENE EXPRESSION; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; TISSUE DISTRIBUTION;

EID: 0035009932     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.2.277     Document Type: Review

References (95)

1. Antisense oligonucleotide-based therapeutics
2. Molecular mechanisms of action of antisense drugs
3. Basic principles of antisense therapeutics
4. Antisense therapeutics: Is it as simple as complementary base recognition
5. Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides
6. Characterization of a potent and specific class of antisense oligonucleotide inhibitors of human protein kinase C-α expression
7. Preclinical development of antisense therapeutics
8. Pharmacological activity of antisense oligonucleotides in animal models of disease
9. A single-injection protein kinase A-directed antisense treatment to inhibit tumor growth
10. Pleiotropic cell-division defects and apoptosis induced by interference with surviving function
11. L expression sensitizes normal human keratinocytes and epithelial cells to apoptotic stimuli
12. Antisense oligonucleotides as therapeutic agents - Is the bullet really magical?
13. A nonantisense sequence-selective effect of a phosphorothioate oligodeoxynucleotide directed against the epidermal growth factor receptor in A431 cells
14. Phosphorothioate oligode-oxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors and remove it from low affinity binding sites on extracellular matrix
15. Toxicity of oligodeoxynucleotide therapeutic agents
16. Pharmacokinetics of antisense oligonucleotides
17. Pharmacokinetic properties of phosphorothioate oligonucleotides in humans
18. Pharmacokinetic properties of phosphorothioates in animals - Absorption, distribution, metabolism and elimination
19. In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration
20. Histological localization of phosphorothioate oligodeoxynucleotides in normal rodent tissue
21. Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues
22. In vitro cellular uptake, distribution and metabolism of oligonucleotides
23. Cell and tissue distribution of synthetic oligonucleotides in healthy and tumor-bearing nude mice
24. Sequence independent plasma and tissue pharmacokinetics for 3 antisense phosphorothioate oligonucleotides: Mouse to man
25. Does antisense exist?
26. Phosphorothioate oligodeoxynucleotides: Antisense or anti-protein?
27. Immune stimulation by oligonucleotides
28. Therapeutic applications of CpG-containing oligodeoxynucleotides
29. Effects of RNA secondary structure on cellular antisense activity
30. Implication of RNA structure on antisense oligonucleotide hybridization kinetics
31. Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms
32. Site specificity of the inhibitory effects of oligo(nucleoside methylphosphonate)s complementary to the acceptor splice junction of herpes simplex virus Type 1 immediate early mRNA
33. Oligodeoxynucleoside phosphoramidites and phosphorothioates as inhibitors of human immunodeficiency virus
34. Repair of thalassemic human B-globin mRNA in mammalian cells by antisense oligonucleotides
35. DNA antisense therapy for asthma in an animal model
36. Inhibition of protein kinase C-α expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides
37. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase
38. Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis
39. Treatment of retinitis induced by cytomegalovirus using intravitreal formivirsen (ISIS 2922)
40. Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region
41. Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA
42. The role of apoptosis within the retina of coronavirus-infected mice
43. Invest
44. Pharmacokinetics of a potential human cytomegalovirus therapeutic, a phosphorothioate oligonucleotide, after intravitreal injections in the rabbit
45. Pharmacokinetics of an antisense oligonucleotide injected intravitreally in monkeys
46. B expression by antisense oligonucleotides alters a neuronal phenotype in the rod pathway of the developing rat retina
47. Antisense knockdown of GLAST, a glial glutamate transporter, compromises retinal function
48. Targeted delivery of an antisense oligonucleotide in the retina: Uptake, distribution, stability and effect
49. Phase I safety and pharmacokinetic profile of an ICAM-1 antisense oligodeoxynucleotide (ISIS 2302)
50. Clinical development of phosphorothioate (P=S) antisense oligodeoxynucleotide inhibitors of PKC-a mRNA (Isis 3521, CGP 64128A) and C-raf kinase (Isis 5132, CGP 69846A)
51. Safety and tolerance of phosphorothioates in humans
52. BCL-2 antisense therapy in patients with non-Hodgkins lymphoma
53. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of steroid-dependent Crohn's disease
54. c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A)
55. Vascular endothelial growth factor and ocular neovascularization
56. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model
57. Vascular endothelial growth factor and the eye: Biochemical mechanisms of action and implications for novel therapies
58. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability
59. Mechanisms of retinal and choroidal neovascularization
60. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins
61. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy
62. Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor
63. Potentiation of cell migration by adhesion-dependent cooperative signals from the GTPase Rac and Raf kinase
64. Death to a blood vessel, death to a tumor
65. Protein kinase G mediates vascular endothelial growth factor-induced raf-1 activation and proliferation in human endothelial cells
66. Anti-sense oligonucleotides block angiogenesis in newly developed model of retinal neovascularization presenting with hemorrhage and subsequent fibrovascular membrane formation
67. Theory and Practice
68. Reduction of fibronectin expression by intravitreal administration of antisense oligonucleotides
69. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCβ inhibition with LY333531
70. Suppression of retinal neovascularization by the NF-kβ inhibitor pyrrolidine dithiocarbamate in mice
71. The role of αv integrins during angiogenesis
72. Definition of two angiogenic pathways by distinct alpha v integrins
73. 5 in ocular neovascular diseases
74. Treatment of non-infectious intermediate and posterior uveitis with the humanized anti-Tac mAb: A Phase I/II clinical trial
75. Retinal ischemia-reperfusion injury attenuated by blocking of adhesion molecules of vascular endothelium
76. Role of P-selectin in endotoxin-induces uveitis
77. Antiviral efficacy of therapeutic oligonucleotide in corneal epithelial cells and keratocytes in vitro
78. Global data on blindness
79. Bax antisense oligonucleotides reduce axotomy-induced retinal ganglion cell death in vivo by reduction of Bax protein expression
80. Role of map kinase in down regulation of NaKC1 cotransport in human pigmented ciliary epithelial cells
81. EGF and tyrosine kinase modulate basal NaKC1 cotransport in human PE cells
82. A new glaucoma anti-scarring agent
83. Effect and localization of a TGF-β1 antisense oligonucleotide in conjunctival scarring - A potential new anti-scarring strategy in glaucoma surgery
84. Peptide nucleic acids (PNA): Potential antiviral agents
85. Morpholino antisense oligomers: The case for an RNase H-independent structural type
86. Efficacy of antibodies to adhesion molecules, CD11a or CD18, in rabbit models of uveitis
87. Intercellular adhesion molecule-1 in proliferative vitreoretinopathy
88. Humanized antibodies against the alpha-chain of the IL-2 receptor and against the beta-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases
89. CpG motifs in bacterial DNA trigger direct B-cell activation
90. Oligonucleotide modifications determine the magnitude of B-cell stimulation by CpG motifs
91. Chemically modified oligonucleotides exhibit decreased immune stimulation in mice
92. Effect of different chemically modified oligodeoxynucleotides on immune stimulation